



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-VEGF Reference Antibody (bevacizumab)	Lot.No.:	P72045
Target:	VEGF	Catalog:	CHA099
Target Accession:	P15692	Concentration :	1 mg/mL
Clonality:	Monoclonal	Isotype:	Human IgG1
Reactivity:	Human	Molecular Weight (kDa) :	150 kDa
Application:	FCM, Block, In Vivo, ELISA	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

Purity: SDS-PAGE

Purity: SEC-HPLC




Anti- Human VEGF (Bevacizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti- Human VEGF (Bevacizumab) is 97.8%, determined by SEC-HPLC.

Bioactivity: ELISA



Immobilized human VEGFA (His Tag, 2µg/mL) can bind to Anti- Human VEGF (Bevacizumab) with an EC50 of 0.003018 ug/mL.

Research in vivo



Anti- Human VEGF (Bevacizumab) inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.

The products are for research use only. Not for use in diagnostic procedures.